Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Genta Incorporated clinical trials
The registry lists 27 studies whose lead sponsor is Genta Incorporated. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 6, 2014.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Genta Incorporated.
- Genta Incorporated27 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 27 of 27.
- Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00017589Phase 2
- Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00024440Phase 3
- Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung CancerStatus unknownNCT00030641Phase 2/3
- Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00017602Phase 3
- Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant MelanomaCompletedNCT00016263Phase 3
- A Study of Tesetaxel Plus Capecitabine in Patients With Solid TumorsStatus unknownNCT01315431Phase 1
- Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric CancerStatus unknownNCT01573468Phase 2
- Tesetaxel as First-line Therapy for Metastatic Breast CancerStatus unknownNCT01221870Phase 2
- Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg CapsulesCompletedNCT01170975Phase 1
- Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate CancerStatus unknownNCT01296243Phase 2
- Tesetaxel for Previously Treated Patients With Bladder CancerStatus unknownNCT01215877Phase 2
- Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast CancerStatus unknownNCT01609127Phase 2
- Genasense as a 2-hour Intravenous Infusion in Subjects With Solid TumorsCompletedNCT00636545Phase 1
- Tesetaxel as Second-line Therapy for Patients With Advanced Gastric CancerStatus unknownNCT01095120Phase 2
- Study of Tesetaxel in Japanese Patients With Solid TumorsStatus unknownNCT01337310Phase 1
- Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal FunctionCompletedNCT00543075Phase 1
- Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric CancerStatus unknownNCT01348009Phase 1/2
- A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without DacarbazineCompletedNCT00542893Phase 1
- Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDHStatus unknownNCT01092585Phase 2
- Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic LeukemiaCompletedNCT00078234Phase 1/2
- Trial of Dacarbazine With or Without Genasense in Advanced MelanomaCompletedNCT00518895Phase 3
- Abraxane and Temodar Plus Genasense in Advanced MelanomaStatus unknownNCT00409383Phase 1
- Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic ImpairmentTerminatedNCT00543205Phase 2/3
- Phase I/II Study of Genasense in Patients With Chronic Lymphocytic LeukemiaCompletedNCT00021749Phase 1/2
- This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)WithdrawnNCT00517218Phase 3
- A Phase I Study of G3139 Subcutaneous in Solid TumorsCompletedNCT00543231Phase 1
- Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00054808Phase 2